Purpose: To investigate the efficacy of plasma rich in growth factors (PRGF)® for the treatment of alveolar osteitis compared to a positive control Alvogyl®.
Methods: This single centre, single blind, randomised, two treatment, parallel study was conducted in a UK dental hospital. All healthy adults who presented with alveolar osteitis following tooth extraction over a 3 month period were invited to participate. Each socket was randomised and treated with one of two treatment modalities, a test treatment PRGF® or a positive control Alvogyl®. Following treatment, patients were reviewed at 3 and 7 days by a second clinician blinded to the treatment given. Outcome measures included pain, exposed bone, inflammation, halitosis, dysgeusia and quality of life assessment.
Results: 38 patients with data from 44 sockets, 22 in the PRGF® group and 22 in the Alvogyl® group, were analysed. The PRGF® group demonstrated significantly faster bone coverage as well as significantly reduced inflammation and halitosis (p<0.05) compared to the control group receiving Alvogyl®. There was no significant difference for pain, quality of life measures or dysgeusia between the groups.
Conclusion: PRGF® predictably treated alveolar osteitis
following tooth extraction compared to the conventional standard treatment of
Alvogyl® which has been used for many years. PRGF could be considered as an
alternative treatment for alveolar osteitis, and indeed appears to have
significant advantages over Alvogel®.
- alveolar osteitis
- plasma rich in growth factors
- bone healing